Rare diseases
Investigational molecules
Locations
Back to Germany1 444 clinical trials in Hochheim Am Main, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)Phase III randomized trial of elecoglipron to assess safety and weight loss in adults with obesity or overweight, with or without type 2 diabetes
GermanyDurvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma
GermanyPhase 1/2 Study of Oral TRI-611 in Adults With Advanced ALK‑Positive Non‑Small Cell Lung Cancer
GermanyEffectiveness and Safety of INTESTIFIX in Removing Vancomycin‑Resistant Enterococci Colonization in Immunocompromised Patients – drug combination
GermanyA Phase III Study of Elafibranor in Adults with Primary Sclerosing Cholangitis to Assess Efficacy and Safety
GermanySwitching to Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults with HIV-1: A Phase 3 Randomized Study
GermanySwitching to lenacapavir-based drug combination vs cabotegravir-based drug combination in virologically suppressed adults with HIV-1
GermanyStudy of LY3484356 (imlunestrant) with Tamoxifen Citrate and Goserelin Acetate in Premenopausal Women with ER‑Positive, HER2‑Negative Early Breast Cancer
GermanyStudy of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients
GermanyEfficacy and Safety of Depemokimab for Early Intervention in Adults and Adolescents with Type 2 Asthma at Risk of Exacerbations
GermanyStudy of nirmatrelvir and remdesivir to achieve viral clearance in immunocompromised patients with persistent COVID-19
GermanyGermanyThe busiest research cities in the country
What the registry says about research in the country
Innovative research focusing on Gaucher disease and Niemann-Pick disease, exploring new therapeutic approaches for these challenging genetic conditions. Studies aim to evaluate novel treatments for improving neurological symptoms and overall patient outcomes.
Clinical investigations evaluating venglustat and nizubaglustat's effectiveness in managing disease progression.
Research centered on treating Mucopolysaccharidosis Type II (Hunter Syndrome) and Pompe disease, with multiple studies investigating innovative enzyme replacement therapies and novel drug combinations.
Evaluation of treatments like JR-141 and cipaglucosidase alfa for improved patient outcomes.
Studies focused on preventing respiratory syncytial virus infections in older adults, with particular attention to vaccine development and immune response assessment.
Investigation of revaccination strategies and long-term protection against respiratory infections.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
